Ignite Creation Date:
2025-12-25 @ 1:24 AM
Ignite Modification Date:
2025-12-27 @ 3:42 AM
Study NCT ID:
NCT00687193
Status:
COMPLETED
Last Update Posted:
2013-03-25
First Post:
2008-05-22
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D001172', 'term': 'Arthritis, Rheumatoid'}], 'ancestors': [{'id': 'D001168', 'term': 'Arthritis'}, {'id': 'D007592', 'term': 'Joint Diseases'}, {'id': 'D009140', 'term': 'Musculoskeletal Diseases'}, {'id': 'D012216', 'term': 'Rheumatic Diseases'}, {'id': 'D003240', 'term': 'Connective Tissue Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D001327', 'term': 'Autoimmune Diseases'}, {'id': 'D007154', 'term': 'Immune System Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'C479163', 'term': 'tofacitinib'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'ClinicalTrials.gov_Inquiries@pfizer.com', 'phone': '1-800-718-1021', 'title': 'Pfizer ClinicalTrials.gov Call Center', 'organization': 'Pfizer, Inc.'}, 'certainAgreement': {'otherDetails': 'Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.', 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}}, 'adverseEventsModule': {'description': 'The same event may appear as both an adverse event (AE) and a serious adverse event (SAE). However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.', 'eventGroups': [{'id': 'EG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.', 'otherNumAtRisk': 53, 'otherNumAffected': 14, 'seriousNumAtRisk': 53, 'seriousNumAffected': 0}, {'id': 'EG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.', 'otherNumAtRisk': 53, 'otherNumAffected': 16, 'seriousNumAtRisk': 53, 'seriousNumAffected': 3}, {'id': 'EG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.', 'otherNumAtRisk': 52, 'otherNumAffected': 19, 'seriousNumAtRisk': 52, 'seriousNumAffected': 2}, {'id': 'EG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.', 'otherNumAtRisk': 53, 'otherNumAffected': 22, 'seriousNumAtRisk': 53, 'seriousNumAffected': 2}, {'id': 'EG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.', 'otherNumAtRisk': 54, 'otherNumAffected': 22, 'seriousNumAtRisk': 54, 'seriousNumAffected': 1}, {'id': 'EG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.', 'otherNumAtRisk': 52, 'otherNumAffected': 16, 'seriousNumAtRisk': 52, 'seriousNumAffected': 1}], 'otherEvents': [{'term': 'Abdominal discomfort', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Constipation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Dental caries', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Diarrhoea', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 2}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gastritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Gingivitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Stomatitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Bronchitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Infections and infestations'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 2}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Nasopharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 6}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 4}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 6}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 8}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 6}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Pharyngitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 1}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Upper respiratory tract infection', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Contusion', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 2}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Fall', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 3}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 3}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood cholesterol increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 2}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Low density lipoprotein increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 6}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypercholesterolaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 2}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 3}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hyperlipidaemia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 6}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 3}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Metabolism and nutrition disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Rheumatoid arthritis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 2}], 'organSystem': 'Musculoskeletal and connective tissue disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Headache', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 3}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 2}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 1}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Hypertension', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 3}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Upper respiratory tract inflammation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 2}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'seriousEvents': [{'term': 'Gastric ulcer perforation', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Herpes zoster', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Herpes zoster oticus', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Fibula fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Spinal compression fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 1}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Tendon rupture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Tibia fracture', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Injury, poisoning and procedural complications', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Alanine aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Aspartate aminotransferase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Blood creatine phosphokinase increased', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Investigations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Post herpetic neuralgia', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 1}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Nervous system disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Atelectasis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 1}], 'organSystem': 'Respiratory, thoracic and mediastinal disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Rheumatoid vasculitis', 'stats': [{'groupId': 'EG000', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG001', 'numAtRisk': 53, 'numAffected': 1}, {'groupId': 'EG002', 'numAtRisk': 52, 'numAffected': 0}, {'groupId': 'EG003', 'numAtRisk': 53, 'numAffected': 0}, {'groupId': 'EG004', 'numAtRisk': 54, 'numAffected': 0}, {'groupId': 'EG005', 'numAtRisk': 52, 'numAffected': 0}], 'organSystem': 'Vascular disorders', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '2'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '36', 'groupId': 'OG001'}, {'value': '38', 'groupId': 'OG002'}, {'value': '45', 'groupId': 'OG003'}, {'value': '49', 'groupId': 'OG004'}, {'value': '8', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 12', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in painful and tender joint count; \\>= 20% improvement in swollen joint count; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP).', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.'}, {'type': 'SECONDARY', 'title': 'Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4 and 8', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (LOCF)', 'categories': [{'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}, {'value': '18', 'groupId': 'OG002'}, {'value': '35', 'groupId': 'OG003'}, {'value': '29', 'groupId': 'OG004'}, {'value': '3', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (LOCF)', 'categories': [{'measurements': [{'value': '19', 'groupId': 'OG000'}, {'value': '25', 'groupId': 'OG001'}, {'value': '32', 'groupId': 'OG002'}, {'value': '43', 'groupId': 'OG003'}, {'value': '42', 'groupId': 'OG004'}, {'value': '5', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (LOCF)', 'categories': [{'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '33', 'groupId': 'OG001'}, {'value': '35', 'groupId': 'OG002'}, {'value': '46', 'groupId': 'OG003'}, {'value': '47', 'groupId': 'OG004'}, {'value': '6', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, and 8', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in painful and tender joint count; \\>= 20% improvement in swollen joint count; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP)at each visit.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.'}, {'type': 'SECONDARY', 'title': 'Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '52', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (LOCF)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}, {'value': '6', 'groupId': 'OG002'}, {'value': '17', 'groupId': 'OG003'}, {'value': '12', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (LOCF)', 'categories': [{'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}, {'value': '15', 'groupId': 'OG002'}, {'value': '29', 'groupId': 'OG003'}, {'value': '25', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (LOCF)', 'categories': [{'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '20', 'groupId': 'OG001'}, {'value': '23', 'groupId': 'OG002'}, {'value': '33', 'groupId': 'OG003'}, {'value': '36', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (LOCF)', 'categories': [{'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}, {'value': '24', 'groupId': 'OG002'}, {'value': '37', 'groupId': 'OG003'}, {'value': '39', 'groupId': 'OG004'}, {'value': '4', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8 and 12', 'description': 'ACR50 response: greater than or equal to (\\>=) 50 percent (%) improvement in painful and tender joint count; \\>= 50% improvement in swollen joint count; and \\>= 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP) at each visit.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.'}, {'type': 'SECONDARY', 'title': 'Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (LOCF)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '1', 'groupId': 'OG002'}, {'value': '5', 'groupId': 'OG003'}, {'value': '4', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (LOCF)', 'categories': [{'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}, {'value': '9', 'groupId': 'OG002'}, {'value': '14', 'groupId': 'OG003'}, {'value': '9', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (LOCF)', 'categories': [{'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '13', 'groupId': 'OG002'}, {'value': '20', 'groupId': 'OG003'}, {'value': '22', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (LOCF)', 'categories': [{'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}, {'value': '14', 'groupId': 'OG002'}, {'value': '26', 'groupId': 'OG003'}, {'value': '28', 'groupId': 'OG004'}, {'value': '1', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8 and 12', 'description': 'ACR70 response: greater than or equal to (\\>=) 70 percent (%) improvement in painful and tender joint count; \\>= 70% improvement in swollen joint count; and \\>= 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP) at each visit.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.'}, {'type': 'SECONDARY', 'title': 'Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (LOCF)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '0', 'groupId': 'OG003'}, {'value': '0', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (LOCF)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '0', 'groupId': 'OG002'}, {'value': '2', 'groupId': 'OG003'}, {'value': '3', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (LOCF)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '3', 'groupId': 'OG002'}, {'value': '7', 'groupId': 'OG003'}, {'value': '5', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (LOCF)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}, {'value': '2', 'groupId': 'OG002'}, {'value': '8', 'groupId': 'OG003'}, {'value': '6', 'groupId': 'OG004'}, {'value': '0', 'groupId': 'OG005'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Week 2, 4, 8 and 12', 'description': 'ACR90 response: greater than or equal to (\\>=) 90 percent (%) improvement in painful and tender joint count; \\>= 90% improvement in swollen joint count; and \\>= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP) at each visit.', 'unitOfMeasure': 'participants', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Score Based on 28-Joints Count Using C-reactive Protein [DAS28-3(CRP)]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks. Missing values were not imputed.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-0.56', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '-1.03', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-1.01', 'spread': '0.13', 'groupId': 'OG002'}, {'value': '-1.65', 'spread': '0.13', 'groupId': 'OG003'}, {'value': '-1.63', 'spread': '0.13', 'groupId': 'OG004'}, {'value': '-0.20', 'spread': '0.13', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-0.82', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '-1.29', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-1.65', 'spread': '0.13', 'groupId': 'OG002'}, {'value': '-2.33', 'spread': '0.13', 'groupId': 'OG003'}, {'value': '-2.14', 'spread': '0.13', 'groupId': 'OG004'}, {'value': '-0.23', 'spread': '0.13', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 51, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-0.98', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '-1.63', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-1.95', 'spread': '0.13', 'groupId': 'OG002'}, {'value': '-2.62', 'spread': '0.13', 'groupId': 'OG003'}, {'value': '-2.55', 'spread': '0.13', 'groupId': 'OG004'}, {'value': '-0.15', 'spread': '0.13', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-1.09', 'spread': '0.13', 'groupId': 'OG000'}, {'value': '-1.71', 'spread': '0.13', 'groupId': 'OG001'}, {'value': '-2.02', 'spread': '0.13', 'groupId': 'OG002'}, {'value': '-2.81', 'spread': '0.13', 'groupId': 'OG003'}, {'value': '-2.70', 'spread': '0.13', 'groupId': 'OG004'}, {'value': '-0.12', 'spread': '0.13', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': "The DAS28-3 (CRP) score is a measure of the perticipant's disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints) and CRP. DAS28-3 (CRP) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.\n\nChange = value at observation minus value at baseline", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Disease Activity Score Based on 28-Joints Count Using Erythrocyte Sedimentation Rate [DAS28-4(ESR)]', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=52, 53, 50, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-0.52', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-0.93', 'spread': '0.14', 'groupId': 'OG001'}, {'value': '-1.00', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '-1.66', 'spread': '0.15', 'groupId': 'OG003'}, {'value': '-1.58', 'spread': '0.14', 'groupId': 'OG004'}, {'value': '-0.25', 'spread': '0.15', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 51)', 'categories': [{'measurements': [{'value': '-0.79', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-1.32', 'spread': '0.15', 'groupId': 'OG001'}, {'value': '-1.69', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '-2.42', 'spread': '0.15', 'groupId': 'OG003'}, {'value': '-2.31', 'spread': '0.14', 'groupId': 'OG004'}, {'value': '-0.23', 'spread': '0.15', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 50, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-1.03', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-1.68', 'spread': '0.15', 'groupId': 'OG001'}, {'value': '-2.05', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '-2.92', 'spread': '0.15', 'groupId': 'OG003'}, {'value': '-2.87', 'spread': '0.14', 'groupId': 'OG004'}, {'value': '-0.12', 'spread': '0.15', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-1.10', 'spread': '0.15', 'groupId': 'OG000'}, {'value': '-1.74', 'spread': '0.15', 'groupId': 'OG001'}, {'value': '-2.20', 'spread': '0.15', 'groupId': 'OG002'}, {'value': '-3.05', 'spread': '0.15', 'groupId': 'OG003'}, {'value': '-2.98', 'spread': '0.14', 'groupId': 'OG004'}, {'value': '-0.10', 'spread': '0.15', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': "The DAS28-4 (ESR) score is a measure of the participant's disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints), participant's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.\n\nChange = score at observation minus score at baseline.", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-0.10', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.15', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.28', 'spread': '0.06', 'groupId': 'OG002'}, {'value': '-0.39', 'spread': '0.06', 'groupId': 'OG003'}, {'value': '-0.40', 'spread': '0.06', 'groupId': 'OG004'}, {'value': '0.06', 'spread': '0.06', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-0.07', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.25', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.38', 'spread': '0.06', 'groupId': 'OG002'}, {'value': '-0.54', 'spread': '0.06', 'groupId': 'OG003'}, {'value': '-0.51', 'spread': '0.06', 'groupId': 'OG004'}, {'value': '0.03', 'spread': '0.06', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 50, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-0.17', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.36', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.49', 'spread': '0.06', 'groupId': 'OG002'}, {'value': '-0.59', 'spread': '0.06', 'groupId': 'OG003'}, {'value': '-0.63', 'spread': '0.06', 'groupId': 'OG004'}, {'value': '0.18', 'spread': '0.06', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-0.19', 'spread': '0.06', 'groupId': 'OG000'}, {'value': '-0.38', 'spread': '0.06', 'groupId': 'OG001'}, {'value': '-0.55', 'spread': '0.06', 'groupId': 'OG002'}, {'value': '-0.67', 'spread': '0.06', 'groupId': 'OG003'}, {'value': '-0.68', 'spread': '0.06', 'groupId': 'OG004'}, {'value': '0.18', 'spread': '0.06', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.\n\nChange = score at observation minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Painful and Tender Joint Counts', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-4.14', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '-5.13', 'spread': '0.97', 'groupId': 'OG001'}, {'value': '-5.29', 'spread': '0.99', 'groupId': 'OG002'}, {'value': '-8.48', 'spread': '0.98', 'groupId': 'OG003'}, {'value': '-7.73', 'spread': '0.96', 'groupId': 'OG004'}, {'value': '-2.03', 'spread': '0.98', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-5.92', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '-6.95', 'spread': '0.98', 'groupId': 'OG001'}, {'value': '-8.41', 'spread': '0.99', 'groupId': 'OG002'}, {'value': '-11.35', 'spread': '0.98', 'groupId': 'OG003'}, {'value': '-10.41', 'spread': '0.97', 'groupId': 'OG004'}, {'value': '-1.12', 'spread': '0.98', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 51, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-6.27', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '-8.80', 'spread': '0.98', 'groupId': 'OG001'}, {'value': '-9.65', 'spread': '0.99', 'groupId': 'OG002'}, {'value': '-12.89', 'spread': '0.98', 'groupId': 'OG003'}, {'value': '-12.16', 'spread': '0.97', 'groupId': 'OG004'}, {'value': '-0.49', 'spread': '0.99', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-7.05', 'spread': '0.98', 'groupId': 'OG000'}, {'value': '-10.01', 'spread': '0.99', 'groupId': 'OG001'}, {'value': '-10.08', 'spread': '1.00', 'groupId': 'OG002'}, {'value': '-13.67', 'spread': '0.99', 'groupId': 'OG003'}, {'value': '-12.81', 'spread': '0.97', 'groupId': 'OG004'}, {'value': '-0.67', 'spread': '1.00', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Weeks 2, 4, 8 and 12', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Swollen Joint Count (SJC)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-3.19', 'spread': '0.69', 'groupId': 'OG000'}, {'value': '-3.85', 'spread': '0.68', 'groupId': 'OG001'}, {'value': '-2.58', 'spread': '0.70', 'groupId': 'OG002'}, {'value': '-6.93', 'spread': '0.69', 'groupId': 'OG003'}, {'value': '-5.95', 'spread': '0.68', 'groupId': 'OG004'}, {'value': '-1.58', 'spread': '0.69', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-4.57', 'spread': '0.69', 'groupId': 'OG000'}, {'value': '-6.10', 'spread': '0.69', 'groupId': 'OG001'}, {'value': '-6.15', 'spread': '0.70', 'groupId': 'OG002'}, {'value': '-8.85', 'spread': '0.69', 'groupId': 'OG003'}, {'value': '-8.15', 'spread': '0.68', 'groupId': 'OG004'}, {'value': '-1.87', 'spread': '0.69', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 51, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-5.25', 'spread': '0.69', 'groupId': 'OG000'}, {'value': '-7.08', 'spread': '0.69', 'groupId': 'OG001'}, {'value': '-7.15', 'spread': '0.70', 'groupId': 'OG002'}, {'value': '-10.04', 'spread': '0.69', 'groupId': 'OG003'}, {'value': '-10.52', 'spread': '0.68', 'groupId': 'OG004'}, {'value': '-1.70', 'spread': '0.70', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-5.76', 'spread': '0.69', 'groupId': 'OG000'}, {'value': '-7.94', 'spread': '0.70', 'groupId': 'OG001'}, {'value': '-7.75', 'spread': '0.70', 'groupId': 'OG002'}, {'value': '-10.44', 'spread': '0.70', 'groupId': 'OG003'}, {'value': '-10.73', 'spread': '0.68', 'groupId': 'OG004'}, {'value': '-1.29', 'spread': '0.70', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.', 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': "Change From Baseline in Patient's Assessment of Pain", 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-8.63', 'spread': '2.94', 'groupId': 'OG000'}, {'value': '-16.70', 'spread': '2.94', 'groupId': 'OG001'}, {'value': '-19.13', 'spread': '3.01', 'groupId': 'OG002'}, {'value': '-29.03', 'spread': '2.97', 'groupId': 'OG003'}, {'value': '-26.45', 'spread': '2.92', 'groupId': 'OG004'}, {'value': '-1.46', 'spread': '2.98', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-12.97', 'spread': '2.96', 'groupId': 'OG000'}, {'value': '-21.19', 'spread': '2.98', 'groupId': 'OG001'}, {'value': '-26.06', 'spread': '3.01', 'groupId': 'OG002'}, {'value': '-36.65', 'spread': '2.97', 'groupId': 'OG003'}, {'value': '-35.16', 'spread': '2.95', 'groupId': 'OG004'}, {'value': '-2.73', 'spread': '2.98', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 50, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-17.57', 'spread': '2.97', 'groupId': 'OG000'}, {'value': '-26.15', 'spread': '2.99', 'groupId': 'OG001'}, {'value': '-30.37', 'spread': '3.01', 'groupId': 'OG002'}, {'value': '-41.84', 'spread': '2.97', 'groupId': 'OG003'}, {'value': '-43.08', 'spread': '2.95', 'groupId': 'OG004'}, {'value': '1.65', 'spread': '3.01', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-18.38', 'spread': '2.97', 'groupId': 'OG000'}, {'value': '-22.33', 'spread': '3.00', 'groupId': 'OG001'}, {'value': '-34.37', 'spread': '3.02', 'groupId': 'OG002'}, {'value': '-42.91', 'spread': '3.01', 'groupId': 'OG003'}, {'value': '-43.79', 'spread': '2.95', 'groupId': 'OG004'}, {'value': '-1.06', 'spread': '3.03', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': "Change from Baseline in Patient's Assessment of Arthritis Pain -VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) was computed as Week 2, 4, 8 or 12 values minus baseline value. A negative value in change from baseline indicates an improvement.\n\nChange = value at observation minus value at baseline.", 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': "Change From Baseline in Patient's Global Assessment of Arthritis", 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-7.66', 'spread': '2.96', 'groupId': 'OG000'}, {'value': '-15.25', 'spread': '2.97', 'groupId': 'OG001'}, {'value': '-20.32', 'spread': '3.04', 'groupId': 'OG002'}, {'value': '-27.06', 'spread': '2.99', 'groupId': 'OG003'}, {'value': '-26.80', 'spread': '2.94', 'groupId': 'OG004'}, {'value': '-1.73', 'spread': '3.00', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-11.22', 'spread': '2.98', 'groupId': 'OG000'}, {'value': '-23.17', 'spread': '3.00', 'groupId': 'OG001'}, {'value': '-27.03', 'spread': '3.04', 'groupId': 'OG002'}, {'value': '-36.64', 'spread': '2.99', 'groupId': 'OG003'}, {'value': '-35.96', 'spread': '2.97', 'groupId': 'OG004'}, {'value': '-3.31', 'spread': '3.00', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 50, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-16.66', 'spread': '2.99', 'groupId': 'OG000'}, {'value': '-24.60', 'spread': '3.01', 'groupId': 'OG001'}, {'value': '-28.78', 'spread': '3.04', 'groupId': 'OG002'}, {'value': '-41.97', 'spread': '2.99', 'groupId': 'OG003'}, {'value': '-41.13', 'spread': '2.97', 'groupId': 'OG004'}, {'value': '0.79', 'spread': '3.03', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-16.29', 'spread': '2.99', 'groupId': 'OG000'}, {'value': '-20.91', 'spread': '3.03', 'groupId': 'OG001'}, {'value': '-34.59', 'spread': '3.05', 'groupId': 'OG002'}, {'value': '-43.55', 'spread': '3.03', 'groupId': 'OG003'}, {'value': '-41.86', 'spread': '2.97', 'groupId': 'OG004'}, {'value': '-1.02', 'spread': '3.05', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly. Change = score at observation minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': "Change From Baseline in Physician's Global Assessment of Arthritis", 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-13.97', 'spread': '2.64', 'groupId': 'OG000'}, {'value': '-15.86', 'spread': '2.63', 'groupId': 'OG001'}, {'value': '-18.10', 'spread': '2.70', 'groupId': 'OG002'}, {'value': '-31.59', 'spread': '2.66', 'groupId': 'OG003'}, {'value': '-25.93', 'spread': '2.61', 'groupId': 'OG004'}, {'value': '-6.09', 'spread': '2.66', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-23.31', 'spread': '2.65', 'groupId': 'OG000'}, {'value': '-26.22', 'spread': '2.67', 'groupId': 'OG001'}, {'value': '-30.45', 'spread': '2.70', 'groupId': 'OG002'}, {'value': '-41.21', 'spread': '2.66', 'groupId': 'OG003'}, {'value': '-37.07', 'spread': '2.64', 'groupId': 'OG004'}, {'value': '-9.70', 'spread': '2.66', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 51, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-21.99', 'spread': '2.66', 'groupId': 'OG000'}, {'value': '-32.04', 'spread': '2.67', 'groupId': 'OG001'}, {'value': '-36.92', 'spread': '2.70', 'groupId': 'OG002'}, {'value': '-45.98', 'spread': '2.66', 'groupId': 'OG003'}, {'value': '-44.66', 'spread': '2.64', 'groupId': 'OG004'}, {'value': '-6.84', 'spread': '2.69', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-25.38', 'spread': '2.66', 'groupId': 'OG000'}, {'value': '-33.47', 'spread': '2.69', 'groupId': 'OG001'}, {'value': '-36.89', 'spread': '2.71', 'groupId': 'OG002'}, {'value': '-49.38', 'spread': '2.70', 'groupId': 'OG003'}, {'value': '-48.36', 'spread': '2.64', 'groupId': 'OG004'}, {'value': '-8.35', 'spread': '2.72', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity; very good and 100 mm = worst disease activity; very poor. Change = score at observation minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in C- Reactive Protein (CRP) (mg/L)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'title': 'Week 2 (n=53, 53, 51, 52, 54, 52)', 'categories': [{'measurements': [{'value': '-5.69', 'spread': '2.24', 'groupId': 'OG000'}, {'value': '-16.61', 'spread': '2.24', 'groupId': 'OG001'}, {'value': '-17.32', 'spread': '2.29', 'groupId': 'OG002'}, {'value': '-22.50', 'spread': '2.26', 'groupId': 'OG003'}, {'value': '-24.95', 'spread': '2.22', 'groupId': 'OG004'}, {'value': '1.02', 'spread': '2.26', 'groupId': 'OG005'}]}]}, {'title': 'Week 4 (n=52, 51, 51, 52, 52, 52)', 'categories': [{'measurements': [{'value': '-5.56', 'spread': '2.25', 'groupId': 'OG000'}, {'value': '-16.26', 'spread': '2.27', 'groupId': 'OG001'}, {'value': '-22.20', 'spread': '2.29', 'groupId': 'OG002'}, {'value': '-24.47', 'spread': '2.26', 'groupId': 'OG003'}, {'value': '-24.59', 'spread': '2.25', 'groupId': 'OG004'}, {'value': '0.59', 'spread': '2.26', 'groupId': 'OG005'}]}]}, {'title': 'Week 8 (n=51, 51, 51, 52, 52, 50)', 'categories': [{'measurements': [{'value': '-9.79', 'spread': '2.27', 'groupId': 'OG000'}, {'value': '-16.71', 'spread': '2.27', 'groupId': 'OG001'}, {'value': '-23.80', 'spread': '2.29', 'groupId': 'OG002'}, {'value': '-23.56', 'spread': '2.26', 'groupId': 'OG003'}, {'value': '-26.03', 'spread': '2.25', 'groupId': 'OG004'}, {'value': '5.27', 'spread': '2.29', 'groupId': 'OG005'}]}]}, {'title': 'Week 12 (n=51, 49, 50, 49, 52, 48)', 'categories': [{'measurements': [{'value': '-8.88', 'spread': '2.27', 'groupId': 'OG000'}, {'value': '-18.34', 'spread': '2.30', 'groupId': 'OG001'}, {'value': '-23.97', 'spread': '2.30', 'groupId': 'OG002'}, {'value': '-25.11', 'spread': '2.30', 'groupId': 'OG003'}, {'value': '-26.14', 'spread': '2.25', 'groupId': 'OG004'}, {'value': '8.22', 'spread': '2.32', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Change = value at observation minus value at baseline.', 'unitOfMeasure': 'mg/L', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Area Under Curve (AUC) for Change From Baseline in American College of Rheumatology-N (ACR-N)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'OG000'}, {'value': '53', 'groupId': 'OG001'}, {'value': '52', 'groupId': 'OG002'}, {'value': '53', 'groupId': 'OG003'}, {'value': '54', 'groupId': 'OG004'}, {'value': '52', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '498.47', 'spread': '341.96', 'groupId': 'OG000'}, {'value': '1876.4', 'spread': '341.96', 'groupId': 'OG001'}, {'value': '2573.0', 'spread': '345.23', 'groupId': 'OG002'}, {'value': '3887.4', 'spread': '341.96', 'groupId': 'OG003'}, {'value': '3628.9', 'spread': '338.78', 'groupId': 'OG004'}, {'value': '-2415', 'spread': '345.23', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': "ACR-N = calculated for each participant by taking lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of remaining 5 components of ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The AUC for ACR-N is measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute AUC.", 'unitOfMeasure': 'units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were handled using the Last Observation Carried Forward (LOCF) method.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in Euro Quality of Life (EQ-5D)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '0.10', 'spread': '0.03', 'groupId': 'OG000'}, {'value': '0.21', 'spread': '0.03', 'groupId': 'OG001'}, {'value': '0.28', 'spread': '0.03', 'groupId': 'OG002'}, {'value': '0.33', 'spread': '0.03', 'groupId': 'OG003'}, {'value': '0.33', 'spread': '0.03', 'groupId': 'OG004'}, {'value': '-0.04', 'spread': '0.03', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Change = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Physical Functioning Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.62', 'spread': '1.09', 'groupId': 'OG000'}, {'value': '6.23', 'spread': '1.11', 'groupId': 'OG001'}, {'value': '5.83', 'spread': '1.13', 'groupId': 'OG002'}, {'value': '9.59', 'spread': '1.11', 'groupId': 'OG003'}, {'value': '8.61', 'spread': '1.08', 'groupId': 'OG004'}, {'value': '-2.53', 'spread': '1.12', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Physical Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.15', 'spread': '1.18', 'groupId': 'OG000'}, {'value': '4.42', 'spread': '1.20', 'groupId': 'OG001'}, {'value': '6.17', 'spread': '1.21', 'groupId': 'OG002'}, {'value': '8.91', 'spread': '1.20', 'groupId': 'OG003'}, {'value': '7.77', 'spread': '1.17', 'groupId': 'OG004'}, {'value': '-0.72', 'spread': '1.22', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Bodily Pain Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '5.94', 'spread': '1.08', 'groupId': 'OG000'}, {'value': '7.81', 'spread': '1.10', 'groupId': 'OG001'}, {'value': '9.74', 'spread': '1.11', 'groupId': 'OG002'}, {'value': '12.58', 'spread': '1.10', 'groupId': 'OG003'}, {'value': '13.90', 'spread': '1.07', 'groupId': 'OG004'}, {'value': '0.27', 'spread': '1.12', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -General Health Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.12', 'spread': '0.84', 'groupId': 'OG000'}, {'value': '4.76', 'spread': '0.86', 'groupId': 'OG001'}, {'value': '5.37', 'spread': '0.86', 'groupId': 'OG002'}, {'value': '7.57', 'spread': '0.86', 'groupId': 'OG003'}, {'value': '7.61', 'spread': '0.83', 'groupId': 'OG004'}, {'value': '0.16', 'spread': '0.87', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Vitality Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg BID', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.67', 'spread': '0.74', 'groupId': 'OG000'}, {'value': '6.11', 'spread': '0.76', 'groupId': 'OG001'}, {'value': '6.58', 'spread': '0.77', 'groupId': 'OG002'}, {'value': '11.98', 'spread': '0.77', 'groupId': 'OG003'}, {'value': '9.49', 'spread': '0.74', 'groupId': 'OG004'}, {'value': '3.38', 'spread': '0.79', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange =score at Week 12 minus score at baseline', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Social Functioning Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '2.22', 'spread': '1.21', 'groupId': 'OG000'}, {'value': '4.88', 'spread': '1.24', 'groupId': 'OG001'}, {'value': '4.65', 'spread': '1.24', 'groupId': 'OG002'}, {'value': '4.56', 'spread': '1.24', 'groupId': 'OG003'}, {'value': '7.62', 'spread': '1.20', 'groupId': 'OG004'}, {'value': '-0.67', 'spread': '1.25', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Emotional Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.83', 'spread': '1.41', 'groupId': 'OG000'}, {'value': '4.20', 'spread': '1.44', 'groupId': 'OG001'}, {'value': '5.64', 'spread': '1.44', 'groupId': 'OG002'}, {'value': '7.99', 'spread': '1.44', 'groupId': 'OG003'}, {'value': '6.42', 'spread': '1.40', 'groupId': 'OG004'}, {'value': '-1.50', 'spread': '1.47', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Mental Health Domain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.29', 'spread': '1.29', 'groupId': 'OG000'}, {'value': '5.02', 'spread': '1.32', 'groupId': 'OG001'}, {'value': '8.62', 'spread': '1.32', 'groupId': 'OG002'}, {'value': '7.64', 'spread': '1.32', 'groupId': 'OG003'}, {'value': '6.27', 'spread': '1.28', 'groupId': 'OG004'}, {'value': '0.59', 'spread': '1.34', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Physical Component Summary (PCS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.27', 'spread': '0.86', 'groupId': 'OG000'}, {'value': '6.03', 'spread': '0.88', 'groupId': 'OG001'}, {'value': '6.22', 'spread': '0.89', 'groupId': 'OG002'}, {'value': '10.25', 'spread': '0.88', 'groupId': 'OG003'}, {'value': '10.27', 'spread': '0.85', 'groupId': 'OG004'}, {'value': '-1.04', 'spread': '0.89', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}, {'type': 'SECONDARY', 'title': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary (MCS)', 'denoms': [{'units': 'Participants', 'counts': [{'value': '51', 'groupId': 'OG000'}, {'value': '49', 'groupId': 'OG001'}, {'value': '50', 'groupId': 'OG002'}, {'value': '49', 'groupId': 'OG003'}, {'value': '52', 'groupId': 'OG004'}, {'value': '48', 'groupId': 'OG005'}]}], 'groups': [{'id': 'OG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'OG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'classes': [{'categories': [{'measurements': [{'value': '3.00', 'spread': '1.27', 'groupId': 'OG000'}, {'value': '3.99', 'spread': '1.30', 'groupId': 'OG001'}, {'value': '7.09', 'spread': '1.30', 'groupId': 'OG002'}, {'value': '6.15', 'spread': '1.30', 'groupId': 'OG003'}, {'value': '5.52', 'spread': '1.26', 'groupId': 'OG004'}, {'value': '0.15', 'spread': '1.32', 'groupId': 'OG005'}]}]}], 'paramType': 'LEAST_SQUARES_MEAN', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.', 'unitOfMeasure': 'Units on a scale', 'dispersionType': 'Standard Error', 'reportingStatus': 'POSTED', 'populationDescription': 'The full analysis set included all participants who were randomized to the study and received at least 1 dose of study medication. Missing values were not imputed.'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'FG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'FG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'FG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'FG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'FG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '53'}, {'groupId': 'FG001', 'numSubjects': '53'}, {'groupId': 'FG002', 'numSubjects': '52'}, {'groupId': 'FG003', 'numSubjects': '53'}, {'groupId': 'FG004', 'numSubjects': '54'}, {'comment': 'One participant withdrew after randomization but prior to treatment.', 'groupId': 'FG005', 'numSubjects': '52'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '51'}, {'groupId': 'FG001', 'numSubjects': '49'}, {'groupId': 'FG002', 'numSubjects': '50'}, {'groupId': 'FG003', 'numSubjects': '49'}, {'groupId': 'FG004', 'numSubjects': '52'}, {'groupId': 'FG005', 'numSubjects': '48'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '2'}, {'groupId': 'FG001', 'numSubjects': '4'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '4'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '4'}]}], 'dropWithdraws': [{'type': 'Adverse Event', 'reasons': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '2'}, {'groupId': 'FG003', 'numSubjects': '3'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}]}, {'type': 'Lack of Efficacy', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '1'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '0'}, {'groupId': 'FG004', 'numSubjects': '0'}, {'groupId': 'FG005', 'numSubjects': '2'}]}, {'type': 'Protocol Violation', 'reasons': [{'groupId': 'FG000', 'numSubjects': '1'}, {'groupId': 'FG001', 'numSubjects': '2'}, {'groupId': 'FG002', 'numSubjects': '0'}, {'groupId': 'FG003', 'numSubjects': '1'}, {'groupId': 'FG004', 'numSubjects': '2'}, {'groupId': 'FG005', 'numSubjects': '0'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '53', 'groupId': 'BG000'}, {'value': '53', 'groupId': 'BG001'}, {'value': '52', 'groupId': 'BG002'}, {'value': '53', 'groupId': 'BG003'}, {'value': '54', 'groupId': 'BG004'}, {'value': '52', 'groupId': 'BG005'}, {'value': '317', 'groupId': 'BG006'}]}], 'groups': [{'id': 'BG000', 'title': 'CP-690,550 1 mg', 'description': 'Participants were administered 1 milligram (mg) of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'BG001', 'title': 'CP-690,550 3 mg', 'description': 'Participants were administered 3 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'BG002', 'title': 'CP-690,550 5 mg', 'description': 'Participants were administered 5 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'BG003', 'title': 'CP-690,550 10 mg', 'description': 'Participants were administered 10 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'BG004', 'title': 'CP-690,550 15 mg', 'description': 'Participants were administered 15 mg of CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'BG005', 'title': 'Placebo', 'description': 'Participants were administered placebo tablet matched to CP-690,550 orally twice daily for 12 weeks.'}, {'id': 'BG006', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Customized', 'classes': [{'title': '< 18 years', 'categories': [{'measurements': [{'value': '0', 'groupId': 'BG000'}, {'value': '0', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}, {'value': '0', 'groupId': 'BG003'}, {'value': '0', 'groupId': 'BG004'}, {'value': '0', 'groupId': 'BG005'}, {'value': '0', 'groupId': 'BG006'}]}]}, {'title': 'Between 18 and 44 years', 'categories': [{'measurements': [{'value': '8', 'groupId': 'BG000'}, {'value': '11', 'groupId': 'BG001'}, {'value': '13', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '12', 'groupId': 'BG004'}, {'value': '14', 'groupId': 'BG005'}, {'value': '67', 'groupId': 'BG006'}]}]}, {'title': 'Between 45 and 64 years', 'categories': [{'measurements': [{'value': '39', 'groupId': 'BG000'}, {'value': '33', 'groupId': 'BG001'}, {'value': '31', 'groupId': 'BG002'}, {'value': '32', 'groupId': 'BG003'}, {'value': '30', 'groupId': 'BG004'}, {'value': '29', 'groupId': 'BG005'}, {'value': '194', 'groupId': 'BG006'}]}]}, {'title': '>= 65 years', 'categories': [{'measurements': [{'value': '6', 'groupId': 'BG000'}, {'value': '9', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '12', 'groupId': 'BG003'}, {'value': '12', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '56', 'groupId': 'BG006'}]}]}], 'paramType': 'NUMBER', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '42', 'groupId': 'BG000'}, {'value': '47', 'groupId': 'BG001'}, {'value': '44', 'groupId': 'BG002'}, {'value': '44', 'groupId': 'BG003'}, {'value': '44', 'groupId': 'BG004'}, {'value': '43', 'groupId': 'BG005'}, {'value': '264', 'groupId': 'BG006'}]}, {'title': 'Male', 'measurements': [{'value': '11', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '8', 'groupId': 'BG002'}, {'value': '9', 'groupId': 'BG003'}, {'value': '10', 'groupId': 'BG004'}, {'value': '9', 'groupId': 'BG005'}, {'value': '53', 'groupId': 'BG006'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE2'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'QUADRUPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'INVESTIGATOR', 'OUTCOMES_ASSESSOR']}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 318}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2009-03'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-03', 'dispFirstSubmitDate': '2010-11-19', 'completionDateStruct': {'date': '2010-07', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2013-03-19', 'studyFirstSubmitDate': '2008-05-22', 'dispFirstSubmitQcDate': '2010-11-19', 'resultsFirstSubmitDate': '2012-11-26', 'studyFirstSubmitQcDate': '2008-05-23', 'dispFirstPostDateStruct': {'date': '2010-11-29', 'type': 'ESTIMATED'}, 'lastUpdatePostDateStruct': {'date': '2013-03-25', 'type': 'ESTIMATED'}, 'resultsFirstSubmitQcDate': '2012-11-26', 'studyFirstPostDateStruct': {'date': '2008-05-30', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2012-12-25', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2010-07', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12', 'timeFrame': 'Week 12', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in painful and tender joint count; \\>= 20% improvement in swollen joint count; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP).'}], 'secondaryOutcomes': [{'measure': 'Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Weeks 2, 4 and 8', 'timeFrame': 'Week 2, 4, and 8', 'description': 'ACR20 response: greater than or equal to (\\>=) 20 percent (%) improvement in painful and tender joint count; \\>= 20% improvement in swollen joint count; and \\>= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP)at each visit.'}, {'measure': 'Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response', 'timeFrame': 'Week 2, 4, 8 and 12', 'description': 'ACR50 response: greater than or equal to (\\>=) 50 percent (%) improvement in painful and tender joint count; \\>= 50% improvement in swollen joint count; and \\>= 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP) at each visit.'}, {'measure': 'Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response', 'timeFrame': 'Week 2, 4, 8 and 12', 'description': 'ACR70 response: greater than or equal to (\\>=) 70 percent (%) improvement in painful and tender joint count; \\>= 70% improvement in swollen joint count; and \\>= 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP) at each visit.'}, {'measure': 'Number of Participants Achieving American College of Rheumatology 90% (ACR90) Response', 'timeFrame': 'Week 2, 4, 8 and 12', 'description': 'ACR90 response: greater than or equal to (\\>=) 90 percent (%) improvement in painful and tender joint count; \\>= 90% improvement in swollen joint count; and \\>= 90% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire \\[HAQ\\]); and C-Reactive Protein (CRP) at each visit.'}, {'measure': 'Change From Baseline in Disease Activity Score Based on 28-Joints Count Using C-reactive Protein [DAS28-3(CRP)]', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': "The DAS28-3 (CRP) score is a measure of the perticipant's disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints) and CRP. DAS28-3 (CRP) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.\n\nChange = value at observation minus value at baseline"}, {'measure': 'Change From Baseline in Disease Activity Score Based on 28-Joints Count Using Erythrocyte Sedimentation Rate [DAS28-4(ESR)]', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': "The DAS28-4 (ESR) score is a measure of the participant's disease activity. It is based on the painful and tender joint count (28 joints), swollen joint count (28 joints), participant's global assessment of disease activity (mm), and ESR. DAS28-4(ESR) scores range from 0 - 10; higher scores indicated greater affectation due to disease activity.\n\nChange = score at observation minus score at baseline."}, {'measure': 'Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI)', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.\n\nChange = score at observation minus score at baseline.'}, {'measure': 'Change From Baseline in Painful and Tender Joint Counts', 'timeFrame': 'Baseline, Weeks 2, 4, 8 and 12', 'description': 'Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.'}, {'measure': 'Change From Baseline in Swollen Joint Count (SJC)', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement. Change = value at observation minus value at baseline.'}, {'measure': "Change From Baseline in Patient's Assessment of Pain", 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': "Change from Baseline in Patient's Assessment of Arthritis Pain -VAS (0 to 100 mm visual analog scale, 0 being no pain and 100 being most severe pain) was computed as Week 2, 4, 8 or 12 values minus baseline value. A negative value in change from baseline indicates an improvement.\n\nChange = value at observation minus value at baseline."}, {'measure': "Change From Baseline in Patient's Global Assessment of Arthritis", 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'Participants answered: "Considering all the ways your arthritis affects you, how are you feeling today?" Participants responded by using a 0 - 100 mm Visual Analog Scale where 0 = very well and 100 = very poorly. Change = score at observation minus score at baseline.'}, {'measure': "Change From Baseline in Physician's Global Assessment of Arthritis", 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'Physician Global Assessment of Disease Activity was measured on a 0 to 100 mm Visual Analog Scale (VAS), with 0 mm = no disease activity; very good and 100 mm = worst disease activity; very poor. Change = score at observation minus score at baseline.'}, {'measure': 'Change From Baseline in C- Reactive Protein (CRP) (mg/L)', 'timeFrame': 'Baseline, Week 2, 4, 8 and 12', 'description': 'The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement. Change = value at observation minus value at baseline.'}, {'measure': 'Area Under Curve (AUC) for Change From Baseline in American College of Rheumatology-N (ACR-N)', 'timeFrame': 'Baseline, Week 12', 'description': "ACR-N = calculated for each participant by taking lowest percentage improvement in (1) swollen joint count or (2) tender joint count or (3) the median of remaining 5 components of ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The AUC for ACR-N is measure of the area under the curve of the mean change from baseline in ACR-N. The trapezoidal rule was used to compute AUC."}, {'measure': 'Change From Baseline in Euro Quality of Life (EQ-5D)', 'timeFrame': 'Baseline, Week 12', 'description': 'EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state ("confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state. Change = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Physical Functioning Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Physical Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Bodily Pain Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -General Health Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Vitality Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange =score at Week 12 minus score at baseline'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Social Functioning Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Role-Emotional Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) -Mental Health Domain', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Physical Component Summary (PCS)', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}, {'measure': 'Change From Baseline in 36-Item Short-Form Health Survey (SF-36) - Mental Component Summary (MCS)', 'timeFrame': 'Baseline, Week 12', 'description': 'SF-36 is a standardized survey evaluating 8 aspects of functional health and well being: physical and social functioning, physical and emotional role limitations, bodily pain, general health, vitality, mental health. The score for a section is an average of the individual question scores, which are scaled 0-100 (100=highest level of functioning).\n\nChange = score at Week 12 minus score at baseline.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['Phase 2 monotherapy in Japan'], 'conditions': ['Arthritis, Rheumatoid']}, 'referencesModule': {'references': [{'pmid': '39192350', 'type': 'DERIVED', 'citation': 'Hetland ML, Strangfeld A, Bonfanti G, Soudis D, Deuring JJ, Edwards RA. Machine learning prediction and explanatory models of serious infections in patients with rheumatoid arthritis treated with tofacitinib. Arthritis Res Ther. 2024 Aug 27;26(1):153. doi: 10.1186/s13075-024-03376-9.'}, {'pmid': '38958913', 'type': 'DERIVED', 'citation': 'Wright GC, Mysler E, Kwok K, Cadatal MJ, Germino R, Yndestad A, Kinch CD, Ogdie A. Impact of Race on the Efficacy and Safety of Tofacitinib in Rheumatoid Arthritis: Post Hoc Analysis of Pooled Clinical Trials. Rheumatol Ther. 2024 Oct;11(5):1135-1164. doi: 10.1007/s40744-024-00677-y. Epub 2024 Jul 3.'}, {'pmid': '37453736', 'type': 'DERIVED', 'citation': 'Charles-Schoeman C, Hyde C, Guan S, Parikh N, Wang J, Shahbazian A, Stockert L, Andrews J. Relationship Between Paraoxonase-1 Genotype and Activity, and Major Adverse Cardiovascular Events and Malignancies in Patients With Rheumatoid Arthritis Receiving Tofacitinib. J Rheumatol. 2023 Jul 15:jrheum.2023-0112. doi: 10.3899/jrheum.2023-0112. Online ahead of print.'}, {'pmid': '36931693', 'type': 'DERIVED', 'citation': 'Kristensen LE, Danese S, Yndestad A, Wang C, Nagy E, Modesto I, Rivas J, Benda B. Identification of two tofacitinib subpopulations with different relative risk versus TNF inhibitors: an analysis of the open label, randomised controlled study ORAL Surveillance. Ann Rheum Dis. 2023 Jul;82(7):901-910. doi: 10.1136/ard-2022-223715. Epub 2023 Mar 17.'}, {'pmid': '36601090', 'type': 'DERIVED', 'citation': 'Hansen KE, Mortezavi M, Nagy E, Wang C, Connell CA, Radi Z, Litman HJ, Adami G, Rossini M. Fracture in clinical studies of tofacitinib in rheumatoid arthritis. Ther Adv Musculoskelet Dis. 2022 Dec 27;14:1759720X221142346. doi: 10.1177/1759720X221142346. eCollection 2022.'}, {'pmid': '36600185', 'type': 'DERIVED', 'citation': 'Curtis JR, Yamaoka K, Chen YH, Bhatt DL, Gunay LM, Sugiyama N, Connell CA, Wang C, Wu J, Menon S, Vranic I, Gomez-Reino JJ. Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Ann Rheum Dis. 2023 Mar;82(3):331-343. doi: 10.1136/ard-2022-222543. Epub 2022 Dec 5.'}, {'pmid': '36526796', 'type': 'DERIVED', 'citation': 'Winthrop KL, Yndestad A, Henrohn D, Danese S, Marsal S, Galindo M, Woolcott JC, Jo H, Kwok K, Shapiro AB, Jones TV, Diehl A, Su C, Panes J, Cohen SB. Influenza Adverse Events in Patients with Rheumatoid Arthritis, Ulcerative Colitis, or Psoriatic Arthritis in the Tofacitinib Clinical Development Programs. Rheumatol Ther. 2023 Apr;10(2):357-373. doi: 10.1007/s40744-022-00507-z. Epub 2022 Dec 17.'}, {'pmid': '34870800', 'type': 'DERIVED', 'citation': 'Winthrop KL, Curtis JR, Yamaoka K, Lee EB, Hirose T, Rivas JL, Kwok K, Burmester GR. Clinical Management of Herpes Zoster in Patients With Rheumatoid Arthritis or Psoriatic Arthritis Receiving Tofacitinib Treatment. Rheumatol Ther. 2022 Feb;9(1):243-263. doi: 10.1007/s40744-021-00390-0. Epub 2021 Dec 6.'}, {'pmid': '33127856', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Wang L, Chen C, Kwok K, Biswas P, Shapiro A, Madsen A, Wollenhaupt J. Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme. RMD Open. 2020 Oct;6(3):e001395. doi: 10.1136/rmdopen-2020-001395.'}, {'pmid': '32816215', 'type': 'DERIVED', 'citation': 'Panaccione R, Isaacs JD, Chen LA, Wang W, Marren A, Kwok K, Wang L, Chan G, Su C. Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Dig Dis Sci. 2021 Aug;66(8):2732-2743. doi: 10.1007/s10620-020-06560-4. Epub 2020 Aug 20.'}, {'pmid': '31512746', 'type': 'DERIVED', 'citation': 'Suzuki M, Shoji S, Miyoshi S, Krishnaswami S. Model-Based Comparison of Dose-Response Profiles of Tofacitinib in Japanese Versus Western Rheumatoid Arthritis Patients. J Clin Pharmacol. 2020 Feb;60(2):198-208. doi: 10.1002/jcph.1514. Epub 2019 Sep 12.'}, {'pmid': '28143815', 'type': 'DERIVED', 'citation': 'Cohen SB, Tanaka Y, Mariette X, Curtis JR, Lee EB, Nash P, Winthrop KL, Charles-Schoeman C, Thirunavukkarasu K, DeMasi R, Geier J, Kwok K, Wang L, Riese R, Wollenhaupt J. Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials. Ann Rheum Dis. 2017 Jul;76(7):1253-1262. doi: 10.1136/annrheumdis-2016-210457. Epub 2017 Jan 31.'}, {'pmid': '26275429', 'type': 'DERIVED', 'citation': 'Charles-Schoeman C, Burmester G, Nash P, Zerbini CA, Soma K, Kwok K, Hendrikx T, Bananis E, Fleischmann R. Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2016 Jul;75(7):1293-301. doi: 10.1136/annrheumdis-2014-207178. Epub 2015 Aug 14.'}, {'pmid': '25496464', 'type': 'DERIVED', 'citation': 'Tanaka Y, Takeuchi T, Yamanaka H, Nakamura H, Toyoizumi S, Zwillich S. Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study. Mod Rheumatol. 2015 Jul;25(4):514-21. doi: 10.3109/14397595.2014.995875.'}, {'pmid': '25047021', 'type': 'DERIVED', 'citation': 'Cohen S, Radominski SC, Gomez-Reino JJ, Wang L, Krishnaswami S, Wood SP, Soma K, Nduaka CI, Kwok K, Valdez H, Benda B, Riese R. Analysis of infections and all-cause mortality in phase II, phase III, and long-term extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheumatol. 2014 Nov;66(11):2924-37. doi: 10.1002/art.38779.'}], 'seeAlsoLinks': [{'url': 'https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921040&StudyName=Comparison%20Of%205%20CP-690%2C550%20Doses%20Vs.%20Placebo%2C%20For%20The%20Treatment%20Of%20Rheumatoid%20Arthritis%20In%20Japan', 'label': 'To obtain contact information for a study center near you, click here.'}]}, 'descriptionModule': {'briefSummary': 'To evaluate the dose-response relationship of 5 dose of CP-690,550, compared to placebo for the treatment of signs and symptoms in patients with active RA who failed an adequate trial of therapy with at least 1 DMARD in a 12-week therapy.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '70 Years', 'minimumAge': '20 Years', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Subjects must have failed an adequate trial of therapy with at least 1 DMARD due to lack of efficacy or toxicity.\n\nExclusion Criteria:\n\n* Current therapy with any DMARD'}, 'identificationModule': {'nctId': 'NCT00687193', 'briefTitle': 'Comparison Of 5 CP-690,550 Doses Vs. Placebo, For The Treatment Of Rheumatoid Arthritis In Japan', 'organization': {'class': 'INDUSTRY', 'fullName': 'Pfizer'}, 'officialTitle': 'A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Confirm Dose Responsiveness Following 12 Weeks Of The Administration Of CP-690,550 (5 Doses) Or Placebo In Subjects With Active Rheumatoid Arthritis Inadequately Responding To At Least 1 DMARD', 'orgStudyIdInfo': {'id': 'A3921040'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'PLACEBO_COMPARATOR', 'label': 'Placebo', 'interventionNames': ['Drug: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 10mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 15mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 1mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 3mg', 'interventionNames': ['Drug: CP-690,550']}, {'type': 'EXPERIMENTAL', 'label': 'CP-690,550, 5mg', 'interventionNames': ['Drug: CP-690,550']}], 'interventions': [{'name': 'Placebo', 'type': 'DRUG', 'description': 'Placebo BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['Placebo']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '10mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 10mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '15mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 15mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '1mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 1mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '3mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 3mg']}, {'name': 'CP-690,550', 'type': 'DRUG', 'description': '5mg BID, 3 blinded tablets administered BID for 12 weeks', 'armGroupLabels': ['CP-690,550, 5mg']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Nagoya', 'state': 'Aichi-ken', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.18147, 'lon': 136.90641}}, {'city': 'Chiba', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.6, 'lon': 140.11667}}, {'city': 'Narashino', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.68184, 'lon': 140.04152}}, {'city': 'Yotukaidou', 'state': 'Chiba', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Fukuoka', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.6, 'lon': 130.41667}}, {'city': 'Iiduka', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Kitakyushu', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.85181, 'lon': 130.85034}}, {'city': 'Kurume', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.31667, 'lon': 130.51667}}, {'city': 'Sawara-ku', 'state': 'Fukuoka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Fukushima', 'state': 'Fukushima', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 37.75, 'lon': 140.46667}}, {'city': 'Takasaki', 'state': 'Gunma', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 36.33333, 'lon': 139.01667}}, {'city': 'Higashihiroshima', 'state': 'Hiroshima', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.40861, 'lon': 132.73682}}, {'city': 'Hiroshima', 'state': 'Hiroshima', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.4, 'lon': 132.45}}, {'city': 'Asahikawa', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 43.77063, 'lon': 142.36489}}, {'city': 'Sapporo', 'state': 'Hokkaido', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 43.06667, 'lon': 141.35}}, {'city': 'Nishinomiya', 'state': 'Hyōgo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.71562, 'lon': 135.33199}}, {'city': 'Tsukuba', 'state': 'Ibaraki', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 36.08333, 'lon': 140.11667}}, {'city': 'Sagamihara', 'state': 'Kanagawa', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.56707, 'lon': 139.24167}}, {'city': 'Koushi', 'state': 'Kumamoto', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Kumamoto', 'state': 'Kumamoto', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 32.80589, 'lon': 130.69181}}, {'city': 'Kyoto', 'state': 'Kyoto', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.02107, 'lon': 135.75385}}, {'city': 'Tsu', 'state': 'Mie-ken', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.73333, 'lon': 136.51667}}, {'city': 'Sendai', 'state': 'Miyagi', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 38.26667, 'lon': 140.86667}}, {'city': 'Nagasaki', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 32.75, 'lon': 129.88333}}, {'city': 'Ohmura', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Sasebo', 'state': 'Nagasaki', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.16834, 'lon': 129.72502}}, {'city': 'Kashihara', 'state': 'Nara', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.95, 'lon': 135.78333}}, {'city': 'Ōita', 'state': 'Oita Prefecture', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 33.23333, 'lon': 131.6}}, {'city': 'Kawachi-Nagano', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.44108, 'lon': 135.58283}}, {'city': 'Osaka', 'state': 'Osaka', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 34.69379, 'lon': 135.50107}}, {'city': 'Ureshino-shi', 'state': 'Saga-ken', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Kawagoe-shi', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Kitamoto', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 36.03322, 'lon': 139.53775}}, {'city': 'Saitama', 'state': 'Saitama', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 35.90807, 'lon': 139.65657}}, {'city': 'Arakawa-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Bunkyo-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Musashimurayama-shi', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Setagaya-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Shinjyuku-ku', 'state': 'Tokyo', 'country': 'Japan', 'facility': 'Pfizer Investigational Site'}, {'city': 'Takaoka', 'state': 'Toyama', 'country': 'Japan', 'facility': 'Pfizer Investigational Site', 'geoPoint': {'lat': 36.75, 'lon': 137.01667}}], 'overallOfficials': [{'name': 'Pfizer CT.gov Call Center', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Pfizer'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Pfizer', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}